Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations

NCT06835569 is registered in ClinicalTrials.gov with Alterome Therapeutics, Inc. as lead sponsor.

NCT NCT06835569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06835569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations
Lead sponsor
Alterome Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 5, 2025
Completion date
August 31, 2029
Enrollment
448 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, cancer, crc (colorectal cancer), nsclc (non-small cell lung cancer), pdac - pancreatic ductal adenocarcinoma